uric acid has been researched along with Diabetic Angiopathies in 55 studies
Uric Acid: An oxidation product, via XANTHINE OXIDASE, of oxypurines such as XANTHINE and HYPOXANTHINE. It is the final oxidation product of purine catabolism in humans and primates, whereas in most other mammals URATE OXIDASE further oxidizes it to ALLANTOIN.
uric acid : An oxopurine that is the final oxidation product of purine metabolism.
6-hydroxy-1H-purine-2,8(7H,9H)-dione : A tautomer of uric acid having oxo groups at C-2 and C-8 and a hydroxy group at C-6.
7,9-dihydro-1H-purine-2,6,8(3H)-trione : An oxopurine in which the purine ring is substituted by oxo groups at positions 2, 6, and 8.
Diabetic Angiopathies: VASCULAR DISEASES that are associated with DIABETES MELLITUS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study was to investigate the long-term effective control of serum uric acid by allopurinol on the carotid intima-media thickness (IMT) in patients with type 2 diabetes (T2DM) and asymptomatic hyperuricemia (HUA)." | 9.20 | The Effects of Allopurinol on the Carotid Intima-media Thickness in Patients with Type 2 Diabetes and Asymptomatic Hyperuricemia: A Three-year Randomized Parallel-controlled Study. ( Chen, Y; Liu, P; Wang, D; Wang, H; Wang, Y; Zhang, F, 2015) |
| "This study evaluated the prognostic power of serum uric acid (UA) in predicting adverse events in elderly acute coronary syndrome (ACS) patients with diabetes mellitus (DM)." | 8.02 | Evaluation of the prognostic ability of serum uric acid for elderly acute coronary syndrome patients with diabetes mellitus: a prospective cohort study. ( Chen, Y; Dong, W; Fu, Z; Guo, J; Jiao, Y; Shen, M; Wang, J; Xi, Q; Xue, H; Yang, X, 2021) |
| "Serum uric acid (SUA) elevation has been associated with the main determinants of atherosclerosis and metabolic syndrome, although an independent relationship between SUA and coronary artery disease (CAD) has never been confirmed." | 7.80 | Impact of diabetes on uric acid and its relationship with the extent of coronary artery disease and platelet aggregation: a single-centre cohort study. ( Aimaretti, G; Barbieri, L; Bellomo, G; Cassetti, E; De Luca, G; Marino, P; Nardin, M; Schaffer, A; Sinigaglia, F; Verdoia, M, 2014) |
| "Serum uric acid is a predictor of cardiac events and correlates to N-terminal pro-B-type natriuretic peptide and albuminuria, underscoring the importance of uric acid as a cardiovascular risk marker in patients with diabetes." | 7.78 | Serum uric acid is related to cardiovascular events and correlates with N-terminal pro-B-type natriuretic peptide and albuminuria in patients with diabetes mellitus. ( Clodi, M; Hülsmann, M; Kromoser, H; Luger, A; Neuhold, S; Pacher, R; Prager, R; Resl, M; Riedl, M; Strunk, G; Vila, G, 2012) |
| "The relationship between elevated serum uric acid (SUA) and coronary heart disease (CHD) is discussed controversially." | 7.68 | Association of elevated serum uric acid with coronary heart disease in diabetes mellitus. ( Dannehl, K; Gries, FA; Hauner, H; Rathmann, W, 1993) |
| "A total of 422 patients with type 2 diabetes who were hypertensive [sitting systolic blood pressure (SBP) > or = 140 mmHg and/or diastolic blood pressure (DBP) > or = 90 mmHg] and microalbuminuric [urinary albumin excretion (UAE) 30-300 mg/day] were eligible for the study." | 6.70 | Losartan reduces microalbuminuria in hypertensive microalbuminuric type 2 diabetics. ( Aznar, J; Llisterri, JL; Lozano, JV; Redon, J, 2001) |
| "Hyperuricemia was common in youth with T2D." | 5.51 | Elevated Serum Uric Acid Is Associated With Greater Risk for Hypertension and Diabetic Kidney Diseases in Obese Adolescents With Type 2 Diabetes: An Observational Analysis From the Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) Stu ( Bjornstad, P; El Ghormli, L; Laffel, L; Lynch, J; Nadeau, KJ; Tollefsen, SE; Weinstock, RS, 2019) |
| "The aim of this study was to investigate the long-term effective control of serum uric acid by allopurinol on the carotid intima-media thickness (IMT) in patients with type 2 diabetes (T2DM) and asymptomatic hyperuricemia (HUA)." | 5.20 | The Effects of Allopurinol on the Carotid Intima-media Thickness in Patients with Type 2 Diabetes and Asymptomatic Hyperuricemia: A Three-year Randomized Parallel-controlled Study. ( Chen, Y; Liu, P; Wang, D; Wang, H; Wang, Y; Zhang, F, 2015) |
| "This study evaluated the prognostic power of serum uric acid (UA) in predicting adverse events in elderly acute coronary syndrome (ACS) patients with diabetes mellitus (DM)." | 4.02 | Evaluation of the prognostic ability of serum uric acid for elderly acute coronary syndrome patients with diabetes mellitus: a prospective cohort study. ( Chen, Y; Dong, W; Fu, Z; Guo, J; Jiao, Y; Shen, M; Wang, J; Xi, Q; Xue, H; Yang, X, 2021) |
| " Serum uric acid (SUA) has been associated with cardiovascular diseases (CVD), but no conclusive findings are available nowadays in patients suffering from hypoglycaemia." | 3.88 | Levels of serum uric acid at admission for hypoglycaemia predict 1-year mortality. ( Bonaventura, A; Carbone, F; Cordera, R; Dallegri, F; Gallo, F; Liberale, L; Maggi, D; Montecucco, F; Sacchi, G, 2018) |
| "Over a 20-year period, patients on dapagliflozin were projected to experience relative reductions in the incidence of myocardial infarction (MI), stroke, CV death, and all-cause death of 13." | 3.80 | Modeling effects of SGLT-2 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomes. ( Alperin, P; Cohen, M; Dziuba, J; Goswami, D; Grossman, HL; Hardy, E; Iloeje, U; Perlstein, I; Racketa, J, 2014) |
| "Serum uric acid (SUA) elevation has been associated with the main determinants of atherosclerosis and metabolic syndrome, although an independent relationship between SUA and coronary artery disease (CAD) has never been confirmed." | 3.80 | Impact of diabetes on uric acid and its relationship with the extent of coronary artery disease and platelet aggregation: a single-centre cohort study. ( Aimaretti, G; Barbieri, L; Bellomo, G; Cassetti, E; De Luca, G; Marino, P; Nardin, M; Schaffer, A; Sinigaglia, F; Verdoia, M, 2014) |
| "Increased serum uric acid levels and vascular atherosclerosis are very common in diabetes." | 3.80 | Serum uric acid is associated with arterial stiffness in men with newly diagnosed type 2 diabetes mellitus. ( Sun, H; Xiang, G; Xiang, L; Zhang, J, 2014) |
| "Serum uric acid is a predictor of cardiac events and correlates to N-terminal pro-B-type natriuretic peptide and albuminuria, underscoring the importance of uric acid as a cardiovascular risk marker in patients with diabetes." | 3.78 | Serum uric acid is related to cardiovascular events and correlates with N-terminal pro-B-type natriuretic peptide and albuminuria in patients with diabetes mellitus. ( Clodi, M; Hülsmann, M; Kromoser, H; Luger, A; Neuhold, S; Pacher, R; Prager, R; Resl, M; Riedl, M; Strunk, G; Vila, G, 2012) |
| "The relationship between serum uric acid (SUA) and risk of coronary heart disease (CHD) mortality remains controversial, particularly in diabetic subjects." | 3.74 | Serum uric acid shows a J-shaped trend with coronary mortality in non-insulin-dependent diabetic elderly people. The CArdiovascular STudy in the ELderly (CASTEL). ( Casiglia, E; Mazza, A; Pessina, AC; Rizzato, E; Schiavon, L; Tikhonoff, V; Zamboni, S, 2007) |
| "The relationship between elevated serum uric acid (SUA) and coronary heart disease (CHD) is discussed controversially." | 3.68 | Association of elevated serum uric acid with coronary heart disease in diabetes mellitus. ( Dannehl, K; Gries, FA; Hauner, H; Rathmann, W, 1993) |
| "Insulin sensitivity was assessed by hyperinsulinaemic-euglycaemic clamps and cardiovascular variables were measured." | 2.84 | Comparison of the effects of diets high in animal or plant protein on metabolic and cardiovascular markers in type 2 diabetes: A randomized clinical trial. ( Hornemann, S; Markova, M; Pfeiffer, AFH; Pivovarova, O; Rohn, S; Rudovich, N; Schneeweiss, R; Sucher, S; Thomann, R, 2017) |
| "A total of 422 patients with type 2 diabetes who were hypertensive [sitting systolic blood pressure (SBP) > or = 140 mmHg and/or diastolic blood pressure (DBP) > or = 90 mmHg] and microalbuminuric [urinary albumin excretion (UAE) 30-300 mg/day] were eligible for the study." | 2.70 | Losartan reduces microalbuminuria in hypertensive microalbuminuric type 2 diabetics. ( Aznar, J; Llisterri, JL; Lozano, JV; Redon, J, 2001) |
| "Hyperuricemia was common in youth with T2D." | 1.51 | Elevated Serum Uric Acid Is Associated With Greater Risk for Hypertension and Diabetic Kidney Diseases in Obese Adolescents With Type 2 Diabetes: An Observational Analysis From the Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) Stu ( Bjornstad, P; El Ghormli, L; Laffel, L; Lynch, J; Nadeau, KJ; Tollefsen, SE; Weinstock, RS, 2019) |
| "In 3207 type 2 diabetes patients, seventeen SNPs (single nucleotide polymorphisms) related to uric acid were genotyped." | 1.43 | A causal relationship between uric acid and diabetic macrovascular disease in Chinese type 2 diabetes patients: A Mendelian randomization analysis. ( Bao, Y; Chen, H; He, Z; Hu, C; Jia, W; Jiang, F; Peng, D; Wang, J; Wang, S; Wang, T; Yan, D; Zhang, R, 2016) |
| "Uric acid was higher in subjects without diabetes than in those with diabetes (P = 0." | 1.37 | Uric acid levels are associated with microvascular endothelial dysfunction in patients with Type 1 diabetes. ( da Silva, PB; de Fátima Bevilácqua da Matta, M; Gomes, MB; Matheus, AS; Tibiriçá, E, 2011) |
| "Coronary artery ectasia was defined as a luminal dilatation of at least 1." | 1.35 | [Elevated serum uric acid levels in patients with isolated coronary artery ectasia]. ( Akçakoyun, M; Akpinar, I; Aksu, T; Balbay, Y; Cay, S; Cetin, M; Erbay, AR; Maden, O; Ozcan, F; Sen, N; Sökmen, E; Uygur, B, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 18 (32.73) | 18.7374 |
| 1990's | 10 (18.18) | 18.2507 |
| 2000's | 7 (12.73) | 29.6817 |
| 2010's | 17 (30.91) | 24.3611 |
| 2020's | 3 (5.45) | 2.80 |
| Authors | Studies |
|---|---|
| Jiao, Y | 1 |
| Wang, J | 2 |
| Yang, X | 2 |
| Shen, M | 1 |
| Xue, H | 1 |
| Guo, J | 1 |
| Dong, W | 1 |
| Chen, Y | 2 |
| Xi, Q | 1 |
| Fu, Z | 1 |
| Lyu, J | 1 |
| Li, Z | 1 |
| Wei, H | 1 |
| Liu, D | 1 |
| Chi, X | 1 |
| Gong, DW | 1 |
| Zhao, Q | 1 |
| Tanaka, M | 1 |
| Yamakage, H | 1 |
| Inoue, T | 1 |
| Odori, S | 1 |
| Kusakabe, T | 1 |
| Shimatsu, A | 1 |
| Satoh-Asahara, N | 1 |
| Bonaventura, A | 1 |
| Gallo, F | 1 |
| Carbone, F | 1 |
| Liberale, L | 1 |
| Maggi, D | 1 |
| Sacchi, G | 1 |
| Dallegri, F | 1 |
| Montecucco, F | 1 |
| Cordera, R | 1 |
| Ren, Y | 1 |
| Gao, L | 2 |
| Guo, X | 1 |
| Huo, X | 1 |
| Lu, J | 1 |
| Li, J | 1 |
| Ji, L | 1 |
| Pilemann-Lyberg, S | 1 |
| Hansen, TW | 1 |
| Tofte, N | 1 |
| Winther, SA | 1 |
| Theilade, S | 1 |
| Ahluwalia, TS | 1 |
| Rossing, P | 1 |
| Bjornstad, P | 2 |
| Laffel, L | 1 |
| Lynch, J | 1 |
| El Ghormli, L | 1 |
| Weinstock, RS | 1 |
| Tollefsen, SE | 1 |
| Nadeau, KJ | 1 |
| Xu, Y | 1 |
| Zhu, J | 1 |
| Liu, Y | 1 |
| Shen, J | 1 |
| Shen, C | 1 |
| Matfin, G | 1 |
| Wu, X | 1 |
| Dziuba, J | 1 |
| Alperin, P | 1 |
| Racketa, J | 1 |
| Iloeje, U | 1 |
| Goswami, D | 1 |
| Hardy, E | 1 |
| Perlstein, I | 1 |
| Grossman, HL | 1 |
| Cohen, M | 1 |
| Verdoia, M | 1 |
| Barbieri, L | 1 |
| Schaffer, A | 1 |
| Cassetti, E | 1 |
| Nardin, M | 1 |
| Bellomo, G | 1 |
| Aimaretti, G | 1 |
| Marino, P | 1 |
| Sinigaglia, F | 1 |
| De Luca, G | 1 |
| Zhang, J | 1 |
| Xiang, G | 1 |
| Xiang, L | 1 |
| Sun, H | 1 |
| Maahs, DM | 1 |
| Rivard, CJ | 1 |
| Pyle, L | 1 |
| Rewers, M | 1 |
| Johnson, RJ | 1 |
| Snell-Bergeon, JK | 1 |
| Pafili, K | 1 |
| Katsiki, N | 2 |
| Mikhailidis, DP | 2 |
| Papanas, N | 2 |
| Ding, X | 1 |
| Zheng, X | 1 |
| Xing, A | 1 |
| Wang, D | 2 |
| Qi, S | 1 |
| Wu, Y | 1 |
| Li, H | 1 |
| Wu, S | 1 |
| Hong, J | 1 |
| Liu, P | 1 |
| Wang, H | 1 |
| Zhang, F | 1 |
| Wang, Y | 1 |
| Yan, D | 1 |
| Jiang, F | 1 |
| Zhang, R | 1 |
| Wang, T | 1 |
| Wang, S | 1 |
| Peng, D | 1 |
| He, Z | 1 |
| Chen, H | 1 |
| Bao, Y | 1 |
| Hu, C | 1 |
| Jia, W | 1 |
| Sucher, S | 1 |
| Markova, M | 1 |
| Hornemann, S | 1 |
| Pivovarova, O | 1 |
| Rudovich, N | 1 |
| Thomann, R | 1 |
| Schneeweiss, R | 1 |
| Rohn, S | 1 |
| Pfeiffer, AFH | 1 |
| Sen, N | 1 |
| Ozcan, F | 1 |
| Uygur, B | 1 |
| Aksu, T | 1 |
| Akpinar, I | 1 |
| Cay, S | 1 |
| Cetin, M | 1 |
| Sökmen, E | 1 |
| Akçakoyun, M | 1 |
| Maden, O | 1 |
| Balbay, Y | 1 |
| Erbay, AR | 1 |
| Matheus, AS | 1 |
| Tibiriçá, E | 1 |
| da Silva, PB | 1 |
| de Fátima Bevilácqua da Matta, M | 1 |
| Gomes, MB | 1 |
| Resl, M | 1 |
| Clodi, M | 1 |
| Neuhold, S | 1 |
| Kromoser, H | 1 |
| Riedl, M | 1 |
| Vila, G | 1 |
| Prager, R | 2 |
| Pacher, R | 1 |
| Strunk, G | 1 |
| Luger, A | 1 |
| Hülsmann, M | 1 |
| Fonseca, VA | 1 |
| Maltezos, E | 1 |
| Kayacan, SM | 1 |
| Kazancioğlu, R | 1 |
| Oflaz, H | 1 |
| Tuna, S | 1 |
| LAMAR, CP | 1 |
| Tseng, CH | 1 |
| Mazza, A | 1 |
| Zamboni, S | 1 |
| Rizzato, E | 1 |
| Pessina, AC | 1 |
| Tikhonoff, V | 1 |
| Schiavon, L | 1 |
| Casiglia, E | 1 |
| Waring, WS | 1 |
| McKnight, JA | 1 |
| Webb, DJ | 1 |
| Maxwell, SR | 2 |
| Roche, S | 1 |
| Moinade, S | 1 |
| Muggeo, M | 1 |
| Calabrò, A | 1 |
| Businaro, V | 1 |
| Moghetti, P | 1 |
| Padovan, D | 1 |
| Crepaldi, G | 1 |
| Schneider, H | 1 |
| Pastow, A | 1 |
| Marigo, S | 1 |
| Griesmacher, A | 1 |
| Kindhauser, M | 1 |
| Andert, SE | 1 |
| Schreiner, W | 1 |
| Toma, C | 1 |
| Knoebl, P | 1 |
| Pietschmann, P | 1 |
| Schnack, C | 1 |
| Schernthaner, G | 1 |
| Eggenberger, M | 1 |
| Asayama, K | 1 |
| Uchida, N | 1 |
| Nakane, T | 1 |
| Hayashibe, H | 1 |
| Dobashi, K | 1 |
| Amemiya, S | 1 |
| Kato, K | 1 |
| Nakazawa, S | 1 |
| Gold, A | 1 |
| Rathmann, W | 1 |
| Hauner, H | 1 |
| Dannehl, K | 1 |
| Gries, FA | 1 |
| Elbagir, MN | 1 |
| Eltom, MA | 1 |
| Mahadi, EO | 1 |
| Berne, C | 1 |
| Drabo, PY | 1 |
| Guira, O | 1 |
| Ouandaogo, BJ | 1 |
| Kabore, J | 1 |
| Thomason, H | 1 |
| Sandler, D | 1 |
| Leguen, C | 1 |
| Baxter, MA | 1 |
| Thorpe, GH | 1 |
| Jones, AF | 1 |
| Barnett, AH | 1 |
| Ceriello, A | 1 |
| Bortolotti, N | 1 |
| Pirisi, M | 1 |
| Crescentini, A | 1 |
| Tonutti, L | 1 |
| Motz, E | 1 |
| Russo, A | 1 |
| Giacomello, R | 1 |
| Stel, G | 1 |
| Taboga, C | 1 |
| Lozano, JV | 1 |
| Llisterri, JL | 1 |
| Aznar, J | 1 |
| Redon, J | 1 |
| Seghieri, G | 1 |
| Moruzzo, D | 1 |
| Fascetti, S | 1 |
| Bambini, C | 1 |
| Anichini, R | 1 |
| De Bellis, A | 1 |
| Alviggi, L | 1 |
| Franconi, F | 1 |
| Müller, G | 1 |
| Stammberger, K | 1 |
| Seige, K | 1 |
| Jones, JJ | 1 |
| Watkins, PJ | 1 |
| Owyong, LY | 1 |
| Loh, PP | 1 |
| Kutty, MK | 1 |
| Jogie, B | 1 |
| Olukoga, AO | 1 |
| Erasmus, RT | 1 |
| Akinlade, KS | 1 |
| Okesina, AB | 1 |
| Alanamu, AA | 1 |
| Abu, EA | 1 |
| Kohner, EM | 1 |
| Cappin, JM | 1 |
| Emmrich, R | 1 |
| Feldman, EB | 1 |
| Gluck, FB | 1 |
| Carter, AC | 1 |
| Diamond, HS | 1 |
| Wellmann, KF | 1 |
| Volk, BW | 1 |
| Heyden, S | 1 |
| Berg, G | 1 |
| Bachmann, K | 1 |
| Matzkies, F | 1 |
| Bergner, D | 1 |
| Grabner, W | 1 |
| Bornhofen, E | 1 |
| Stürzenhofecker, P | 1 |
| Sailer, D | 1 |
| Curri, SB | 1 |
| Gligore, V | 1 |
| Hincu, N | 1 |
| Tecuceanu, R | 1 |
| Sopon, E | 1 |
| Hoinărescu, E | 1 |
| Cristea, A | 1 |
| Berenyi, MR | 1 |
| Straus, B | 1 |
| Miglietta, OE | 1 |
| Nolph, KD | 1 |
| Stoltz, ML | 1 |
| Maher, JF | 1 |
| Hayner, NS | 1 |
| Wollenweber, J | 1 |
| Doenecke, P | 1 |
| Greten, H | 1 |
| Hild, R | 1 |
| Nobbe, F | 1 |
| Schmidt, FH | 1 |
| Wagner, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Studies to Treat Or Prevent Pediatric Type 2 Diabetes (STOPP-T2D) Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) Clinical Trial[NCT00081328] | Phase 3 | 699 participants (Actual) | Interventional | 2004-05-31 | Completed | ||
| Effect of Urinary Alkalinization on Urine Uric Acid Precipitation and Crystallization in Adults With Type 1 DiabetesL a Open-label Trial[NCT02502071] | Phase 4 | 45 participants (Actual) | Interventional | 2017-01-31 | Completed | ||
| Effects of Low Intensity Aerobic Exercise Training on the Microvascular Endothelial Function of Patients With Type 1 Diabetes: a Non-pharmacological Interventional Study[NCT02441504] | 22 participants (Actual) | Interventional | 2014-01-31 | Completed | |||
| [NCT00005122] | 0 participants | Observational | 1958-07-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Body mass index (BMI) measured in kg per meters squared. The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time. (NCT00081328)
Timeframe: 24 months
| Intervention | kg per meters squared (Mean) |
|---|---|
| 1 Metformin Alone | 36.7 |
| 2 Metformin + Rosliglitazone | 38.2 |
| 3 Metformin + Lifestyle Program | 35.3 |
Measured by DXA, both whole body scan and AP-spine scan. The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time. In addition, in about 1/3 of participants DXA scans could not be obtained on participants weighing more than 300 pounds (136 kg), the upper limit in size set by the machine manufacturers. Scans were considered invalid if a body part (e.g., arm, leg) was completely off or partially off the scanner, there was hand-hip overlap, or there was motion or movement during the scan. (NCT00081328)
Timeframe: 24 months
| Intervention | g/cm squared (Mean) |
|---|---|
| 1 Metformin Alone | 1.15 |
| 2 Metformin + Rosliglitazone | 1.15 |
| 3 Metformin + Lifestyle Program | 1.15 |
Determined by DXA whole body scan. The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time. In addition, in about 1/3 of participants DXA scans could not be obtained on participants weighing more than 300 pounds (136 kg), the upper limit in size set by the machine manufacturers. Scans were considered invalid if a body part (e.g., arm, leg) was completely off or partially off the scanner, there was hand-hip overlap, or there was motion or movement during the scan. (NCT00081328)
Timeframe: 24 months
| Intervention | kg (Mean) |
|---|---|
| 1 Metformin Alone | 36.1 |
| 2 Metformin + Rosliglitazone | 39.7 |
| 3 Metformin + Lifestyle Program | 32.2 |
Waist circumference (cm) measured at the iliac crest at its outermost point with the measuring tape placed around the participant in a horizontal plane parallel to the floor at the mark and the measurement teken at the end of normal expiration without the tape compressing the skin. The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time. (NCT00081328)
Timeframe: 24 months
| Intervention | cm (Mean) |
|---|---|
| 1 Metformin Alone | 110.8 |
| 2 Metformin + Rosliglitazone | 114.0 |
| 3 Metformin + Lifestyle Program | 108.6 |
A diagnosis was made by an out-of-range value >=95th percentile or systolic >=130 or diastolic >=80 sustained over 6 months or on an anti-hypertensive medication. (NCT00081328)
Timeframe: Data collected at baseline and during follow-up - 2 years to 6.5 years from randomization.
| Intervention | participants (Number) |
|---|---|
| 1 Metformin Alone | 57 |
| 2 Metformin + Rosliglitazone | 53 |
| 3 Metformin + Lifestyle Program | 45 |
A diagnosis was made from out-of-range value >= 130 mg/dL sustained over 6 months or put on lipid lowering medication. (NCT00081328)
Timeframe: Data collected at baseline and during follow-up - 2 years to 6.5 years from randomization.
| Intervention | participants (Number) |
|---|---|
| 1 Metformin Alone | 18 |
| 2 Metformin + Rosliglitazone | 16 |
| 3 Metformin + Lifestyle Program | 15 |
A diagnosis was made by an out-of-range value >=150 mg/dL sustained over 6 months or on appropriate lipid lowering medication. (NCT00081328)
Timeframe: Data collected at baseline and during follow-up - 2 years to 6.5 years from randomization.
| Intervention | participants (Number) |
|---|---|
| 1 Metformin Alone | 20 |
| 2 Metformin + Rosliglitazone | 28 |
| 3 Metformin + Lifestyle Program | 22 |
Insulinogenic index determined from OGTT as difference in insulin at 30 minutes minus 0 minutes divided by difference in glucose at 30 minutes minus 0 minutes. The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time. (NCT00081328)
Timeframe: 24 months
| Intervention | uU/mL divided by mg/dL (Median) |
|---|---|
| 1 Metformin Alone | .75 |
| 2 Metformin + Rosliglitazone | .83 |
| 3 Metformin + Lifestyle Program | .71 |
All participants were followed to 24 months. Insulin sensitivity is measured from OGTT as inverse of fasting insulin (mL/uU). The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time. (NCT00081328)
Timeframe: 24 months
| Intervention | mL/uU (Median) |
|---|---|
| 1 Metformin Alone | 0.037 |
| 2 Metformin + Rosiglitazone | 0.049 |
| 3 Metformin + Lifestyle Program | 0.039 |
Number of serious adverse events reported during the trial. Participant could have multiple episodes reported. (NCT00081328)
Timeframe: Reported as occurred during study follow-up - 2 years to 6.5 years from randomization.
| Intervention | episodes of serious adverse event (Number) |
|---|---|
| 1 Metformin Alone | 42 |
| 2 Metformin + Rosiglitazone | 34 |
| 3 Metformin + Lifestyle Program | 58 |
Defined as A1c persistently >=8% over a 6-month period or persistent metabolic decompensation (inability to wean insulin within 3 months of initiation or the occurrence of a second episode within three months of discontinuing insulin) (NCT00081328)
Timeframe: Study duration - 2 years to 6.5 years of follow up from randomization
| Intervention | participants (Number) | |
|---|---|---|
| Treatment failure | Did not fail treatment during trial | |
| 1 Metformin Alone | 120 | 112 |
| 2 Metformin + Rosliglitazone | 90 | 143 |
| 3 Metformin + Lifestyle Program | 109 | 125 |
Urine uric acid crystals were identified by polarized microscopy (Polarized light imaging Zeiss Axiovert 135; 0.3NA objective), and pictures were captured from each urine sample. UA crystals were defined dichotomously as being present or absent. (NCT02502071)
Timeframe: Day 1 (pre-therapy) and Day 2 (post-therapy)
| Intervention | participants (Number) | |
|---|---|---|
| Day 1 (pre-therapy) | Day 2 (post-therapy) | |
| Sodium Bicarbonate | 14 | 3 |
Urine uric acid were evaluated using a QuantiChrom UA kit assay (DIUA-250) with quantitative colorimetric UA determination at 590 nm (BioAssay System, California, USA). (NCT02502071)
Timeframe: Day 1 (pre-therapy) and Day 2 (post-therapy)
| Intervention | mg/dl (Geometric Mean) | |
|---|---|---|
| Day 1 (pre-therapy) | Day 2 (post-therapy) | |
| Sodium Bicarbonate | 23.81 | 22.30 |
4 reviews available for uric acid and Diabetic Angiopathies
| Article | Year |
|---|---|
Hyperuricemia as an independent predictor of vascular complications and mortality in type 2 diabetes patients: a meta-analysis.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Humans; Hyperuricemia; Male; | 2013 |
Uric acid and diabetes: Is there a link?
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Angiopathies | 2013 |
CHELATION THERAPY OF OCCLUSIVE ARTERIOSCLEROSIS IN DIABETIC PATIENTS.
Topics: Aged; Arteriosclerosis; Blood Urea Nitrogen; Chelation Therapy; Dermatitis; Diabetes Mellitus; Diabe | 1964 |
[Hypertension, Type II diabetes mellitus and macroangiopathy: risk factors and their association].
Topics: Albuminuria; Alcohol Drinking; Diabetes Mellitus, Type 1; Diabetic Angiopathies; Exercise; Female; H | 1994 |
7 trials available for uric acid and Diabetic Angiopathies
| Article | Year |
|---|---|
Beneficial Effects of Ipragliflozin on the Renal Function and Serum Uric Acid Levels in Japanese Patients with Type 2 Diabetes: A Randomized, 12-week, Open-label, Active-controlled Trial.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies | 2020 |
Serum uric acid predicts vascular complications in adults with type 1 diabetes: the coronary artery calcification in type 1 diabetes study.
Topics: Adult; Calcinosis; Coronary Artery Disease; Coronary Vessels; Diabetes Mellitus, Type 1; Diabetic An | 2014 |
The Effects of Allopurinol on the Carotid Intima-media Thickness in Patients with Type 2 Diabetes and Asymptomatic Hyperuricemia: A Three-year Randomized Parallel-controlled Study.
Topics: Adult; Aged; Allopurinol; Asian People; Atherosclerosis; Biomarkers; Blood Pressure; C-Reactive Prot | 2015 |
Comparison of the effects of diets high in animal or plant protein on metabolic and cardiovascular markers in type 2 diabetes: A randomized clinical trial.
Topics: Aged; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Cohort Studies; Dairy Products; Diabe | 2017 |
Lowering serum urate does not improve endothelial function in patients with type 2 diabetes.
Topics: Acetylcholine; Adult; Brachial Artery; Cross-Over Studies; Diabetes Mellitus, Type 2; Diabetic Angio | 2007 |
Losartan reduces microalbuminuria in hypertensive microalbuminuric type 2 diabetics.
Topics: Albuminuria; Antihypertensive Agents; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, | 2001 |
Treatment of diabetic neuropathy with clofibrate.
Topics: Adolescent; Aged; Cholesterol; Clinical Trials as Topic; Clofibrate; Diabetic Angiopathies; Diabetic | 1971 |
44 other studies available for uric acid and Diabetic Angiopathies
| Article | Year |
|---|---|
Evaluation of the prognostic ability of serum uric acid for elderly acute coronary syndrome patients with diabetes mellitus: a prospective cohort study.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Cause of Death; Diabetic Angiopathies; Female; Hum | 2021 |
A potent risk model for predicting new-onset acute coronary syndrome in patients with type 2 diabetes mellitus in Northwest China.
Topics: Acute Coronary Syndrome; Aged; Biomarkers; Blood Pressure; Body Mass Index; China; Cholesterol, LDL; | 2020 |
Levels of serum uric acid at admission for hypoglycaemia predict 1-year mortality.
Topics: Aged; Aged, 80 and over; Biomarkers; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus; Diabet | 2018 |
Interactive effect of serum uric acid and total bilirubin for micro-vascular disease of type 2 diabetes in China.
Topics: Aged; Bilirubin; China; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; D | 2018 |
Uric Acid Is an Independent Risk Factor for Decline in Kidney Function, Cardiovascular Events, and Mortality in Patients With Type 1 Diabetes.
Topics: Adult; Aged; Albuminuria; Biomarkers; Cardiovascular Diseases; Cross-Sectional Studies; Diabetes Mel | 2019 |
Elevated Serum Uric Acid Is Associated With Greater Risk for Hypertension and Diabetic Kidney Diseases in Obese Adolescents With Type 2 Diabetes: An Observational Analysis From the Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) Stu
Topics: Adolescent; Blood Pressure; Child; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephro | 2019 |
Modeling effects of SGLT-2 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomes.
Topics: Amputation, Surgical; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Cardiovascul | 2014 |
Impact of diabetes on uric acid and its relationship with the extent of coronary artery disease and platelet aggregation: a single-centre cohort study.
Topics: Aged; Aged, 80 and over; Cohort Studies; Coronary Angiography; Coronary Artery Disease; Diabetes Mel | 2014 |
Serum uric acid is associated with arterial stiffness in men with newly diagnosed type 2 diabetes mellitus.
Topics: Adult; Age Factors; Atherosclerosis; C-Reactive Protein; Carotid Arteries; China; Cross-Sectional St | 2014 |
Serum uric acid as a predictor of vascular complications in diabetes: an additional case for neuropathy.
Topics: Coronary Artery Disease; Diabetes Mellitus, Type 1; Diabetic Angiopathies; Female; Humans; Male; Uri | 2014 |
High risk factors of atrial fibrillation in type 2 diabetes: results from the Chinese Kailuan study.
Topics: Adult; Aged; Aged, 80 and over; Atrial Fibrillation; China; Diabetes Mellitus, Type 2; Diabetic Angi | 2015 |
A causal relationship between uric acid and diabetic macrovascular disease in Chinese type 2 diabetes patients: A Mendelian randomization analysis.
Topics: Adult; Aged; Asian People; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies | 2016 |
[Elevated serum uric acid levels in patients with isolated coronary artery ectasia].
Topics: Aged; Biomarkers; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Coronary Vessel | 2009 |
Uric acid levels are associated with microvascular endothelial dysfunction in patients with Type 1 diabetes.
Topics: Adult; Analysis of Variance; Biomarkers; Blood Glucose; Coronary Artery Disease; Cross-Sectional Stu | 2011 |
Serum uric acid is related to cardiovascular events and correlates with N-terminal pro-B-type natriuretic peptide and albuminuria in patients with diabetes mellitus.
Topics: Albuminuria; Atherosclerosis; Biomarkers; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic | 2012 |
Comparison of different risk factors that result in endothelial damage leading to diabetic microangiopathy.
Topics: Adult; Antigens; Diabetes Complications; Diabetic Angiopathies; Endothelium, Vascular; Humans; Hyper | 2003 |
Independent association of uric acid levels with peripheral arterial disease in Taiwanese patients with Type 2 diabetes.
Topics: Aged; Arterial Occlusive Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Humans; | 2004 |
Serum uric acid shows a J-shaped trend with coronary mortality in non-insulin-dependent diabetic elderly people. The CArdiovascular STudy in the ELderly (CASTEL).
Topics: Aged; Biomarkers; Blood Glucose; Cholesterol; Coronary Disease; Creatinine; Diabetes Mellitus, Type | 2007 |
[Study of the course of development in 84 non-insulin-dependent diabetics over a 5-to-10-year period. Their therapeutic outcome].
Topics: Adult; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic | 1983 |
[Correlation of metabolic and hemorrheological parameters in diabetes and hyperlipidemia].
Topics: Blood Viscosity; Cholesterol; Cholesterol, HDL; Diabetes Mellitus; Diabetic Angiopathies; Erythrocyt | 1983 |
[The cardiovascular risk profile of long-term diabetics and its relation to kidney function].
Topics: Adolescent; Adult; Aged; Body Weight; Cholesterol; Coronary Disease; Creatinine; Diabetes Complicati | 1982 |
[The behavior of some metabolic and instrumental parameters in diabetics with arteriopathy of the lower extremities treated with increasing doses of glucuronyl-glycosaminoglycano-sulfate].
Topics: Adult; Aged; Blood; Blood Glucose; Cholesterol; Diabetic Angiopathies; Female; Glucuronates; Glycosa | 1980 |
Enhanced serum levels of thiobarbituric-acid-reactive substances in diabetes mellitus.
Topics: Adult; Aged; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus | 1995 |
Antioxidants in the serum of children with insulin-dependent diabetes mellitus.
Topics: Adolescent; Antioxidants; Ascorbic Acid; Child; Diabetes Mellitus, Type 1; Diabetic Angiopathies; Fe | 1993 |
Thiazide therapy for diabetes.
Topics: Benzothiadiazines; Diabetic Angiopathies; Diuretics; Glucose; Glucose Tolerance Test; Humans; Hypert | 1994 |
Association of elevated serum uric acid with coronary heart disease in diabetes mellitus.
Topics: Adolescent; Adult; Aged; Biomarkers; Body Weight; Coronary Disease; Cross-Sectional Studies; Diabete | 1993 |
Pattern of long-term complications in Sudanese insulin-treated diabetic patients.
Topics: Adolescent; Adult; Aged; Biomarkers; Blood Pressure; Cardiovascular Diseases; Cerebrovascular Disord | 1995 |
[Arterial hypertension and diabetes in Ouagadougou (Burkina Faso)].
Topics: Adult; Aged; Burkina Faso; Diabetes Complications; Diabetic Angiopathies; Female; Humans; Hyperchole | 1996 |
Antioxidant status in patients with uncomplicated insulin-dependent and non-insulin-dependent diabetes mellitus.
Topics: Adult; Antioxidants; Ascorbic Acid; Case-Control Studies; Diabetes Mellitus, Type 1; Diabetes Mellit | 1997 |
Total plasma antioxidant capacity predicts thrombosis-prone status in NIDDM patients.
Topics: Antioxidants; Ascorbic Acid; Case-Control Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; | 1997 |
Increase in serum uric acid is selectively associated with stroke in type 2 diabetes.
Topics: Biomarkers; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Stroke; Uric Acid | 2002 |
[Uric acid levels and arterial diseases].
Topics: Adult; Aged; Arterial Occlusive Diseases; Diabetic Angiopathies; Humans; Male; Middle Aged; Uric Aci | 1979 |
Diabetes and its vascular complications in Malaysia.
Topics: Adult; Aged; Blood Glucose; Cerebrovascular Disorders; Cholesterol; Coronary Disease; Diabetes Melli | 1978 |
Plasma urate in diabetes: relationship to glycaemia, glucose disposal, microvascular complications and the variations following oral glucose.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; | 1991 |
Do medical conditions have an influence on central retinal vein occlusions?
Topics: Age Factors; Arterial Occlusive Diseases; Blood Viscosity; Diabetic Angiopathies; Hemoglobins; Human | 1974 |
[Prevention of arteriosclerosis].
Topics: Arteriosclerosis; Cholesterol; Diabetic Angiopathies; Diet Therapy; Female; Gout; Humans; Hyperglyce | 1974 |
Microangiopathy in hyperlipidemia and gout.
Topics: Adolescent; Adult; Age Factors; Aged; Basement Membrane; Biopsy, Needle; Blood Glucose; Body Weight; | 1974 |
[Epidemiology of cerebral vascular occlusions].
Topics: Adult; Age Factors; Cerebrovascular Disorders; Cholesterol; Diabetic Angiopathies; Encephalomalacia; | 1972 |
[Relationship between metabolic diseases and the severity of coronary disease].
Topics: Angina Pectoris; Angiocardiography; Cholesterol; Diabetes Complications; Diabetic Angiopathies; Fema | 1972 |
The diagnostic significance of the finger-tip biopsy in microangiopathies. Pathology of the arteriovenous anastomoses and preterminal circulation.
Topics: Adult; Arteriovenous Anastomosis; Biopsy; Cells, Cultured; Connective Tissue; Diabetic Angiopathies; | 1973 |
[Significance of hyperlipoproteinemia in diabetes mellitus].
Topics: Adult; Cholesterol; Cholinesterases; Diabetes Complications; Diabetes Mellitus; Diabetic Angiopathie | 1973 |
Altered peritoneal permeability in patients with systemic vasculitis.
Topics: Capillary Permeability; Creatinine; Diabetic Angiopathies; Diffusion; Epithelium; Humans; Hypertensi | 1971 |
Metabolic factors in the epidemiology of arterial disease.
Topics: Adult; Age Factors; Arteriosclerosis; Blood Glucose; Blood Pressure; Body Weight; Cerebrovascular Di | 1971 |
[Incidence of hyperlipemia, hyperuricemia, diabetes mellitus, hypertension and overweight in arterial obliterating disease].
Topics: Adult; Aged; Arteriosclerosis Obliterans; Blood Glucose; Body Weight; Cholesterol; Diabetic Angiopat | 1971 |